Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and A Phase IIa, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder (Part 2).


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05434156

Organisation Name: Eleusis Therapeutics

Overal Status: Recruiting

Start Date: October 27, 2022

Last Update: November 14, 2022

Lead Sponsor: Eleusis Therapeutics

Brief Summary: A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).

Conditions:
  • Healthy Volunteers
  • Major Depressive Disorder
  • Depression


Total execution time in seconds: 0.20311594009399